Lamictal, Lamotrigine News

Indianapolis life sciences firm Seradyn Inc. notified the Indiana Department of Workforce Development yesterday that it would close at the end of the year, leaving 114 employees out of work.

ELMlab Abstract BACKGROUND: Borderline personality disorder has long defined definitive treatment.

Busy with other chores, Kathryn Pauley asked her 16-year-old to pick up younger daughter Cheyenne's seizure medicine at a pharmacy.

CiteULike is a free online bibliography manager. Register and you can start organising your references online.

Unknown Source: Detroit Free Press Wordcount: Jun. 5--Busy with other chores, Kathryn Pauley asked her 16-year-old to pick up younger daughter Cheyenne's seizure medicine at a pharmacy.

The Food and Drug Administration has approved an extended-release version of lamotrigine for patients 13 and up with partial onset seizures.

To those who continue to sing the tired old tune that generic drugs are not as effective as brand name drugs, Consumer Reports wants to see the evidence.

Shares of GlaxoSmithKline ticked up Monday after the U.S Food and Drug Administration approved the company's anti-seizure medication, Lamictal XR.

GlaxoSmithKline has announced that the FDAhas approved Lamictal XR Extended-Release Tablets as once-a-day add-on therapy for epilepsy patients 13 years of age or older with partial onset seizures.

The U.S. Food and Drug Administration has approved a dissolvable version of GlaxoSmithKline PLC's blockbuster drug Lamictal, the company said Monday.

The company noted that due to its novel drug-delivery formulation, Lamictal ODT has pleasant taste and disintegrates on the tongue.

ROCKVILLE, Md., May 5, 2009--The FDA posted the following on its website about product labeling for antiepileptic drugs: Suicidal Behavior and Ideation and Antiepileptic Drugs Update 5/5/2009: AED class label changes Manufacturers of antiepileptic drugs or anticonvulsant drugs will update product labeling to include a warning about an increased ...

The Food and Drug Administration has issued new labeling requirements for anti-seizure drugs due to potential increased risk of suicidal behaviors, according to FDA MedWatch .

Continuing their groundbreaking research into the treatment of mood disorders in older adults, psychiatrists at the Weill Cornell Institute of Geriatric Psychiatry at the NewYork-Presbyterian Hospital/Westchester Division in White Plains will begin new studies on the effects of quetiapine and lamotrigine .

The Food and Drug Administration on Tuesday said it approved new labels for epilepsy drugs that include warnings about an increased risk of suicidal thoughts and behaviors associated with the medicines.

The labeling applies to more than 20 medications used to control seizures, psychiatric disorders and nerve pain.

The labeling for the epilepsy drugs Topamax , Lamictal , Tegretol and Trileptal come after the FDA ordered the drugs' labels be updated with warnings about suicidal risks with the medications.

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists identify a therapy's effect on decrease in severity of depressive symptoms as the attribute that most influences their prescribing decisions in bipolar depression.

The study's authors say that women of childbearing age should avoid valproate as a first choice drug for the treatment of epilepsy.

Studies suggest that children of mothers who take Depakote during pregnancy have lower IQs than those of women taking some other anti-seizure drugs which are used as mood stabilizers in bipolar disorder.